Safety of Monoclonal Antibodies in Myeloma

Video

Keith Stewart, MB, ChB from Mayo Clinic in Scottsdale, discusses the use of monoclonal antibodies for treatment in multiple myeloma.

Keith Stewart, MB, ChB from Mayo Clinic in Scottsdale, discusses the use of monoclonal antibodies for treatment in multiple myeloma.

While infusion reactions can occur, pre-medication is recommended. Also, reactions do not usually persist past the first infusion. For daratumumab, these reactions can also affect the upper respiratory system. Also in daratumumab, the agent can affect red cell cross-matching for transfusion. Therefore, all cross-matching should take place before infusions.

To learn more about these treatments, watch Monoclonal Antibodies in Multiple Myeloma.

Related Videos
Related Content
Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit

Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit

April 12th 2024
Article

Over the last 5 years, 57% of drugs approved by the FDA for a cancer-related indication did not show a clinical benefit in confirmatory studies.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Frontline Ibrutinib May Be Effective and Well Tolerated in Low-Risk MCL

Frontline Ibrutinib May Be Effective and Well Tolerated in Low-Risk MCL

April 4th 2024
Article

Findings from this study demonstrated effectiveness with frontline ibrutinib in patients with previously treated, low-risk mantle cell lymphoma regardless of whether rituximab was added.

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

December 1st 2023
Podcast

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

Revumenib Receives Priority Review From the FDA for Acute Leukemia Subset

Revumenib Receives Priority Review From the FDA for Acute Leukemia Subset

March 31st 2024
Article

The new drug application for revumenib is supported by data from the AUGMENT-101 trial of patients with KMT2A-rearranged acute myeloid leukemia or acute lymphoblastic leukemia.

Ibrutinib Plus Venetoclax Provides Survival Benefit in CLL

Ibrutinib Plus Venetoclax Provides Survival Benefit in CLL

March 23rd 2024
Article

Progression-free and overall survival benefits were obtained with MRD-guided ibrutinib plus venetoclax when compared with fludarabine plus cyclophosphamide and rituximab in chronic lymphocytic leukemia.

© 2024 MJH Life Sciences

All rights reserved.